Claims for Patent: 9,605,276

Summary for Patent: 9,605,276

Title:	Replication defective adenovirus vector in vaccination
Abstract:	Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
Inventor(s):	Jones; Frank R (Seattle, WA), Gabitzsch; Elizabeth (Seattle, WA)
Assignee:	Etubics Corporation (Seattle, WA)
Application Number:	14/422,504
Patent Claims:	1. A method of treating a carcinoembryonic antigen (CEA)-expressing cancer in a human in need thereof, the method comprising: administering to the human a single dose of a pharmaceutical composition comprising from 1.times.10.sup.9 to 5.times.10.sup.11 viral particles of a replication-defective vector comprising a nucleic acid sequence encoding a modified carcinoembryonic antigen (CEA) comprising a sequence set forth in SEQ ID NO:5 (YLSGADLNL). 2. The method of claim 1, wherein the human has tumor cells that overexpress CEA as compared with a baseline level in a non-tumor cell. 3. The method of claim 1, wherein the human has pre-existing immunity to Ad5. 4. The method of claim 1, wherein the human has cancer of the colon, rectum, breast, lung, pancreas, thyroid, prostate, or a combination thereof. 5. The method of claim 1, wherein the replication-defective vector is a replication-defective adenoviral vector. 6. The method of claim 5, wherein the replication-defective adenoviral vector has a deletion in an early 2b (E2b) gene region. 7. The method of claim 6, wherein the replication-defective adenoviral vector further comprises a deletion in an early 1 (E1) gene region, a deletion in an early 3 (E3) gene region, a deletion in an early 4 (E4) gene region, or a combination thereof. 8. The method of claim 1, wherein the replication-defective vector comprises a nucleic acid sequence with at least 80% identity to a region in SEQ ID NO: 3 from 1057 to 3165. 9. The method of claim 1, wherein the pharmaceutical composition comprises a dose of at least 10.sup.9 replication-defective viral particles. 10. The method of claim 1, wherein the pharmaceutical composition comprises a dose of at least 10.sup.11 replication-defective viral particles. 11. The method of claim 1, wherein the administering is subcutaneous administration. 12. The method of claim 1, wherein the administering is intradermal, parenteral, intravenous, intramuscular or intraperitoneal administration. 13. The method of claim 1, wherein the human has previously been determined to overexpress CEA in tumor cells as compared with a baseline level in a non-tumor cell. 14. The method of claim 1, further comprising irradiating the human or administering a chemotherapy to the human. 15. The method of claim 1, wherein the pharmaceutical composition is administered to the human at least two times. 16. The method of claim 1, wherein the pharmaceutical composition is administered to the human at an interval of at least two to four weeks or at least three months. 17. The method of claim 1, wherein the pharmaceutical composition is first administered to the human at an interval of at least two to four weeks followed by a subsequent administration of the pharmaceutical composition at an interval of at least three months. 18. The method of claim 1, wherein the pharmaceutical composition further comprises an immune adjuvant. 19. The method of claim 1, further comprising administering to the human a chemotherapy concurrently with or subsequently after administering the pharmaceutical composition. 20. The method of claim 19, wherein the chemotherapy is selected from the group consisting of FOLFOX, pazopanib, sorafenib, oxaliplatin, bevacizunab, Capecitabine, fluoropyrimidine, irinotecan, Mitomycin, Regorafenib, cetuxinab, panitumumab, acetinophen, and a combination thereof. 21. The method of claim 1, wherein the pharmaceutical composition further comprises a vector encoding an antigen selected from the group consisting of p53, HPV E6, HPV E7, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, BAGE, DAM-6, -10, GAGE-1, -2, -8, GAGE-3, -4, -5, -6, -7B, NA88-A, NY-ESO-1, MART-1, MC1R, Gp100, PSA, PSM, Tyrosinase, TRP-1, TRP-2, ART-4, CAMEL, Cyp-B, Her2/neu, hTERT, hTRT, iCE, MUC1, MUC2, PRAME, P15, RU1, RU2, SART-1, SART-3, WT1, AFP, 13-catenin/m, Caspase-8/m, CEA, CDK-4/m, ELF2M, GnT-V, G250, HSP70-2M, HST-2, KIAA0205, MUM-1, MUM-2, MUM-3, Myosin/m, RAGE, SART-2, TRP-2/INT2, 707-AP, Annexin II, CDC27/m, TPI/mber-abl, ETV6/AML, LDLR/FUT, Pml/RARa, and TEL/AML1, and a combination thereof. 22. The method of claim 1, wherein the pharmaceutical composition further comprises a vector encoding an antigen selected from the group consisting of HPV E6, HPV E7, Her2/neu, MUC1, PSA, PSM, or a combination thereof.

Details for Patent 9,605,276

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2032-08-24